5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Gufic Biosciences Ltd.

•
guficbio.comBSE: 509079NSE: GUFICBIO
Market Cap₹ 4,254 Cr.
Current Price
High / Low₹ 468 / 268
Stock P/E57.9
Book Value₹ 68
Price to Book4.15
Dividend Yield0.02 %
ROCE12.5 %
ROE10.0 %
Face Value₹ 1

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2018 • Pharma: 93.8% • Bulk Drugs: 6.2%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Latest quarter profit grew 86.1% YoY, showing strong momentum
  • Company generates healthy free cash flow
  • Company has a consistent dividend-paying track record

CONS

  • Company has delivered a poor profit growth of 7.4% over past five years
  • Operating margins have contracted to 12.3% from 17.1%
  • Though reporting repeated profits, the company pays out little dividend (1.6%)
  • Growth is decelerating - 3Y profit CAGR (-7.5%) trails the 5Y trend (7.4%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.8729012.301165.33152998.801004.5719.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.GUFICBIO424.2557.924254.490.0222.3170.72260.8216.5812.5617.87
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
195215202195203204208205227230231252261
160176165161167166174178195195195206231
Operating Profit35393634363934273236364630
OPM %18.19%18.32%18.07%17.55%17.64%18.91%16.33%12.99%14.25%15.54%15.71%18.21%11.39%
10011020121-10
Interest44345558910899
Depreciation4444445888888
Profit before Tax28313027282926111621212830
Tax %26.49%25.01%24.70%26.07%25.79%25.60%26.48%26.07%25.80%27.23%26.08%25.52%25.53%
Net Profit2123222021221981215162122
2.132.392.232.002.082.171.930.801.201.491.552.052.24

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
246306351379488779691807820940974
223267305327404631556659683790827
Operating Profit2339465284148135147136150148
OPM %9.35%12.69%13.11%13.76%17.21%19.00%19.50%18.26%16.64%15.99%15.16%
14464332432
Interest691014145817253737
Depreciation4451416192217213131
Profit before Tax1430353058127107116948599
Tax %37.21%44.99%37.93%24.69%23.36%24.44%25.31%25.53%25.94%26.13%25.99%
Net Profit916222344968086706374
EPS1.172.122.822.344.569.898.228.596.976.30—
Dividend Payout %4.29%2.36%1.77%2.14%2.19%1.01%1.22%1.16%1.43%1.59%—

COMPOUNDED SALES GROWTH

10 Years:
17%
5 Years:
14%
3 Years:
11%

COMPOUNDED PROFIT GROWTH

10 Years:
24%
5 Years:
7%
3 Years:
-7%

STOCK PRICE CAGR

10 Years:
27%
5 Years:
16%
3 Years:
13%
1 Year:
17%

RETURN ON EQUITY

10 Years:
26%
5 Years:
22%
3 Years:
14%
Last Year:
10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Aug 28

₹ 0.10

Rs.0.1000 per share(10%)Final Dividend

2025

Sep 22

₹ 0.10

Rs.0.1000 per share(10%)Final Dividend

2024

Sep 17

₹ 0.10

Rs.0.1000 per share(10%)Final Dividend

2023

Sep 21

₹ 0.10

Rs.0.1000 per share(10%)Final Dividend

2022

Aug 24

₹ 0.10

Rs.0.1000 per share(10%)Final Dividend

2021

Sep 9

₹ 0.10

Rs.0.1000 per share(10%)Final Dividend

2020

Nov 3

₹ 0.05

Rs.0.0500 per share(5%)Final Dividend

2018

Sep 19

₹ 0.05

Rs.0.0500 per share(5%)Dividend

2017

Aug 28

₹ 0.05

Rs.0.0500 per share(5%)Dividend

2016

Sep 19

₹ 0.05

Rs.0.0500 per share(5%)Dividend

2015

Sep 22

₹ 0.05

Rs.0.0500 per share(5%)Final Dividend

2019

Aug 21

₹ 0.05

Rs.0.0500 per share(5%)Final Dividend

2026

Aug 13

₹ 0.10

Rs.0.1000 per share(10%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital88810101010101010
304668120164259338523591654
61841021286367333313310379
Trade Payables447678117111141130166159199
332155337245508110099
Total Liabilities1752353104074195218601,0931,1701,342
22232483100115160159506491
Capital Work in Progress02103113411703072222
0000001233
63949412294116183200217324
1211111330315297
Cash & Bank67816132747132874
831071731541982222998179129
Total Assets1752353104074195218601,0931,1701,342

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
0121557971391-712344
Cash from Investing-5-9-13-43-7-95-191-102-72-31
Cash from Financing7148-4-79-623482-3732
-11-002517-271445

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
72.5072.5172.5172.5172.5272.5072.5072.5072.50
0.230.230.300.310.320.330.440.420.47
2.382.512.993.393.383.663.743.833.67
Government0.000.000.000.000.000.000.000.000.00
24.8824.7424.2123.7923.7823.5123.3223.2523.36

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-08
Credit Rating

2026-09-08 - Gufic Biosciences Limited has informed the Exchange about Credit Rating

2026-09-07
Shareholders meeting

2026-09-07 - Gufic Biosciences Limited has submitted the Exchange a copy of Scrutinizers report and voting results of 42nd Annual General Meeting held on September 04, 2026

2026-09-04
Shareholders meeting

2026-09-04 - Gufic Biosciences Limited has informed the Exchange regarding Proceedings of 42nd Annual General Meeting held on September 04, 2026

2026-09-02
General Updates

2026-09-02 - Gufic Biosciences Limited has informed the Exchange about Promotion and Change in Designation of Senior Management Personnel

2026-08-21
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-21 - Gufic Biosciences Limited has informed the Exchange about Transcript

2026-08-18
Copy of Newspaper Publication

2026-08-18 - Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of Physical Shares

2026-08-17
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-17 - Gufic Biosciences Limited has informed the Exchange about Link of Recording

2026-08-15
Copy of Newspaper Publication

2026-08-15 - Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Advertisement of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026

2026-08-14
General Updates

2026-08-14 - Gufic Biosciences Limited has submitted to the Exchange the Investor Presentation for the quarter ended June 30, 2026

News

Recent coverage and analyst commentary for GUFICBIO

Loading news…

🤖

AI Stock Analyst

Gufic Biosciences Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login